C2A - Enabling Progress Against Alzheimer's Disease: Power of Diverse Pharmacometrics Approaches

Monday, November 11, 2024

3:15 PM – 4:45 PM MST

Location: Canyon Ballroom

Chair(s)

Julie Stone, PhD

Scientific Assoc. VP
Merck & Co., Inc.
West Point, Pennsylvania, United States
Youfang Cao, PhD

Director of Pharmacometrics
Eisai, Inc
Nutley, New Jersey, United States

Speaker and Panelist(s)

Brian Willis, PhD (he/him/his)

Head of Pharmacometrics
Biogen, Indiana, United States
Ivelina Gueorguieva, PhD (she/her/hers)

Sr Director, Global PK/PD and Pharmacometrics
Eli Lilly and Company, United Kingdom
SR

Seth Robey, PhD (he/him/his)

Director, Quant. Pharmacology & Pharmacometrics
Merck & Co., Inc.
Glen Ridge, New Jersey, United States

Panelist(s)

Stephen Duffull, PhD (he/him/his)

Senior Scientific Advisor
Certara, Otago, New Zealand

Disclosure(s):

Julie A. Stone, PhD: Merck & Co., Inc.: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Youfang Cao, PhD: Eisai Inc: Employment (Ongoing)

Brian A. Willis, PhD: Biogen: Employment (Ongoing); Eisai Inc: Employment (Terminated); Eli Lilly: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Ivelina Gueorguieva, PhD: Eli Lilly: Employment (Ongoing)

Seth Robey, PhD: Merck & Co., Inc.: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Stephen Duffull, PhD: Certara: Employment (Ongoing)

Presentations:

3:15 PM – 3:35 PM MST

Pharmacometrics for the Win: How Modeling Helps Demonstrate Efficacy in Alzheimer’s Disease and Provides Insight into Drug Activity
Speaker: Brian A. Willis, PhD (he/him/his) – Biogen
3:35 PM – 3:55 PM MST

Model Informed Drug Development (MIDD) in Alzheimer’s Disease
Speaker: Ivelina Gueorguieva, PhD (she/her/hers) – Eli Lilly and Company
3:55 PM – 4:15 PM MST

Mapping Longitudinal Biomarker Relationships in Alzheimer’s Disease with Latent Time Joint Mixed Effects Modeling
Speaker: Seth Robey, PhD (he/him/his) – Merck & Co., Inc.
4:15 PM – 4:45 PM MST

Panel Discussion
Panelist: Julie A. Stone, PhD – Merck & Co., Inc.
Panelist: Youfang Cao, PhD – Eisai, Inc
Panelist: Brian A. Willis, PhD (he/him/his) – Biogen
Panelist: Ivelina Gueorguieva, PhD (she/her/hers) – Eli Lilly and Company
Panelist: Stephen Duffull, PhD (he/him/his) – Certara